Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CPA1 | P15085 | 3/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2198547 | 0.89 | ALDH1A1 (0.45) | ALDH1A1CYP2C19LMNAMAPTCPA1 | |
| SCHEMBL4298905 | 0.84 | CPA1 (0.46) | ALDH1A1CYP2C19LMNACPA1CYP3A4 | |
| SCHEMBL4298901 | 0.84 | CPA1 (0.46) | ALDH1A1CYP2C19LMNACPA1CYP3A4 | |
| SCHEMBL5243446 | 0.83 | ALDH1A1 (0.59) | ALDH1A1CYP2C19LMNACPA1CYP3A4 | |
| SCHEMBL22831513 | 0.83 | ALDH1A1 (0.49) | ALDH1A1CYP2C19LMNACPA1PTGS1 | |
| SCHEMBL22831512 | 0.83 | ALDH1A1 (0.49) | ALDH1A1CYP2C19LMNACPA1PTGS1 | |
| SCHEMBL22831433 | 0.81 | CPA1 (0.51) | ALDH1A1CYP2C19LMNAMAPTCPA1 | |
| SCHEMBL9857595 | 0.80 | MAPT (0.44) | ALDH1A1LMNAMAPTPDPK1PPARA | |
| SCHEMBL6228910 | 0.79 | CPA1 (0.44) | ALDH1A1CYP2C19LMNAMAPTCPA1 | |
| SCHEMBL6230273 | 0.79 | CPA1 (0.44) | ALDH1A1CYP2C19LMNAMAPTCPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095227-A1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2418204-A1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | Kyoto University (JP) | 2012-02-15 | — | — | EP | disclosed |
| US-20110087049-A1 | METHOD OF PRODUCING PURIFIED OPTICALLY ACITVE 4-AMINO-3-(SUBSTITUTED PHENYL)BUTANOIC ACID COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED | 2011-04-14 | — | — | US | disclosed |
| EP-2298730-A1 | METHOD OF PRODUCING PURIFIED OPTICALLY ACTIVE 4-AMINO-3-(SUBSTITUTED PHENYL)BUTANOIC ACID COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2011-03-23 | — | — | EP | disclosed |
| EP-1512678-A1 | Process for preparing optically active nitro compounds and cyano compounds | Kanto Kagaku Kabushiki Kaisha (JP) | 2005-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110087049-A1 | METHOD OF PRODUCING PURIFIED OPTICALLY ACITVE 4-AMINO-3-(SUBSTITUTED PHENYL)BUTANOIC ACID COMPOUND | ALAD, OR10J3, ACMSD | ALDH1A1 566/4885CYP2C19 644/4885LMNA 3798/4885 |
| US-20120095227-A1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | CCNL2, ASH2L, AHR | ALDH1A1 2003/4885CYP2C19 291/4885LMNA 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.